

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on January 13, 2003.

*Frank C. Eisenschenk*

Frank C. Eisenschenk, Ph.D., Patent Attorney

15-40  
1/22/03  
INFORMATION DISCLOSURE STATEMENT  
Examining Group 1645  
Patent Application  
Docket No. G-101US05REG  
Serial No. 10/051,681

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Unknown  
Art Unit : 1645  
Applicant(s) : Daniel Cohen and Ilya Chumakov  
Serial No. : 10/051,681  
Filed : January 16, 2002  
Conf. No. : 1458  
For : Treatment of CNS Disorders Using D-Amino Acid Oxidase and D-Aspartate Oxidase Antagonists

RECEIVED

JAN 24 2003

TECH CENTER 1600/2900

Assistant Commissioner for Patents  
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:


In accordance with 37 C.F.R. § 1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

Applicants inadvertently omitted copies of references R85-97 from the IDS package submitted on December 16, 2002. Applicants apologize for any confusion this may cause and request consideration of these references at this time.

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO/SB/08 with initials or other appropriate marks. If any additional fee is required, or to credit any overpayment, please use Deposit Account No. 19-0065.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.56, 1.97, and 1.98 are met by the foregoing statements.

Respectfully submitted,



Frank C. Eisenschenk  
Patent Attorney  
Registration No. 45,332  
Phone No.: 352-375-8100  
Fax No.: 352-372-5800  
Address: Saliwanchik, Lloyd & Saliwanchik  
A Professional Association  
2421 N.W. 41<sup>st</sup> Street, Suite A-1  
Gainesville, FL 32606-6669

FCE/jaj

Attachments: Form PTO/SB/08B (1 page)  
Copies of references cited (13)



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08B (10-01)  
Approved for use through 10/31/2002 OMB 0651-0031  
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

+

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>		<b>RECEIVED</b>  JAN 24 2003  TECH CENTER 1600/2900
		Application Number	10/051,681	
Sheet	1	of	1	
		Filing Date	January 16, 2002	
		First Named Inventor	D. Cohen <i>et al.</i>	
		Group Art Unit	1645	
		Examiner Name	Unassigned	
		Attorney Docket Number	101 US5.REG	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R85	CRUZ, L.J. <i>et al.</i> , "Mutual antagonism in the metabolism of D-valine and D-leucine and antagonism by their analogs", <i>Arch Biochem Biophys.</i> , 1969, 135(1):341-9, PubMed, PMID: 4391341.	
	R86	DE KOK, A. <i>et al.</i> , "Studies on L-amino acid oxidase. I. Effects of pH and competitive inhibitors", <i>Biochim Biophys Acta</i> , 1968, 167(1): 35-47, PubMed, PMID: 5693709.	
	R87	DE MARCHI, W.J. <i>et al.</i> , "The oxidation of glycine by D-amino acid oxidase in extracts of mammalian central nervous tissue", <i>J Neurochem.</i> , 1969, 16(3):355-61. PubMed, PMID: 4389537.	
	R88	MCFARLANE, I.G. <i>et al.</i> , "Metabolism of leucine in protein-calorie-deficient rats", <i>Biochem J.</i> , 1969, 111(4):565-71, PubMed, PMID: 4388242.	
	R89	MECHER, T. <i>et al.</i> , "Presence of L-amino-acid oxidase in the blood in pemphigus, dermatitis herpetiformis Duhring and herpes zoster", <i>Clin. Chim. Acta</i> , 1969, 24(1): 111-20, PubMed, PMID: 5780154.	
	R90	MIZON, J. <i>et al.</i> , "Properties of turkey ( <i>Meleagris gallopavo</i> L.) liver L-amino acid oxidase", <i>Biochim Biophys Acta</i> , 1970, 212(1):33-42 [article in French], PubMed, PMID 5500943.	
	R91	NEIMS, A.H. <i>et al.</i> , "Distribution of D-amino acid oxidase in bovine and human nervous tissues", <i>J Neurochem.</i> , 1966, 13(3):163-8, PubMed, PMID: 4380208.	
	R92	NISHIKIMI, M. <i>et al.</i> , "The occurrence of superoxide anion in the reaction of reduced phenazine methosulfate and molecular oxygen", <i>Biochem Biophys Res Commun.</i> , 1972, 46(2):849-54, PubMed, PMID: 4400444.	
	R93	SHINWARI, M.A. <i>et al.</i> , "Naturally occurring inhibition and activation of avian liver L-amino acid oxidase", 1967, 104(3): 53P - 54P, PubMed, PMID: 6049890.	
	R94	SINGER, S. <i>et al.</i> , "The effects of the administration of sodium benzoate and diethylstilbestrol disulfate on the hepatic levels of several glucocorticoid-sensitive enzymes in adrenalectomized rats", <i>Biochim Biophys Acta.</i> , 1967, 146(2):443-51, PubMed, PMID: 4383683.	
	R95	SIVA SANKAR, D.V. <i>et al.</i> , "The effect of chlorpromazine and of oxygen on the substrate-inhibition of L-amino acid oxidase", <i>Biochem. Med.</i> , 1975(1): 75-82, PubMed, PMID: 1212242.	
	R96	ZELLER, E.A. <i>et al.</i> , "Interaction of ophidian L-amino acid oxidase with its substrates and inhibitors: role of molecular geometry and electron distribution. Communication 6 on ophidian L-amino acid oxidases", <i>Helv. Chim. Acta</i> , 1974:57(8): 2406-20, PubMed, PMID: 4443288.	
	R97	ZIMMERMAN, S.E. <i>et al.</i> , "Immunochemical studies of L-amino acid oxidase", <i>Biochim Biophys Acta</i> , 1971, 229(1):260-70, PubMed, PMID: 5543611.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional) <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

+

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.